Evidence map›Paper›PMID 24465873›Full record

ArticlePloS one2014

fMRI of retina-originated phosphenes experienced by patients with Leber congenital amaurosis.

Manzar Ashtari, Laura Cyckowski, Alborz Yazdi, Amanda Viands, Kathleen Marshall, István Bókkon, Albert Maguire, Jean Bennett

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Frontiers in neurology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Review
  10. Article
  11. Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  12. Article
  13. Article
  14. Gene therapy for the nervous system: challenges and new strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Manzar AshtariDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Laura CyckowskiDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Alborz YazdiDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Amanda ViandsDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Kathleen MarshallCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
István BókkonVision Research Institute, Lowell, Massachusetts, United States of America.
Albert MaguireCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America ; F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Pennsylvania, United States of America ; Ophthalmology Department, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Jean BennettCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America ; F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Pennsylvania, United States of America.
Children's Hospital of Philadelphia · USUniversity of Massachusetts Lowell · USUniversity of Pennsylvania · US

Funding

Therapeutic approaches for ABCA4-associated disordersR24EY019861 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALLIKMETS, RANDO L · 2011 to 2015
$7.2M
Broad Spectrum Molecular Therapy for Blinding Retina DisordersDP1EY023177 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BENNETT, JEAN · 2012 to 2015
$3.2M
Plasticity of the human visual system studied in response to retinal gene therapyR01EY025287 · NEI · UNIVERSITY OF PENNSYLVANIA · PI ASHTARI, MANZAR · 2016 to 2020
$2.4M
Longitudinal Neuroimaging of Leber's Congenital Amaurosis After Gene TherapyR21EY020662 · NEI · CHILDREN'S HOSP OF PHILADELPHIA · PI ASHTARI, MANZAR · 2011 to 2012
$440k
NCCDPHP CDC HHS 8DP1EY023177NEI NIH HHS DP1 EY023177NEI NIH HHS R01 EY025287NEI NIH HHS R21 EY020662NEI NIH HHS R21EY020662NEI NIH HHS R24 EY019861NEI NIH HHS R24EY019861
6 · The paper itself

Abstract

A phenomenon characterized by the experience of seeing light without any light actually entering the eye is called phosphenes or photopsias. Phosphenes can occur spontaneously or via induction by external stimuli. Previous reports regarding phosphenes have primarily focused on externally induced phosphenes such as by applying alternating or direct current to the cortex. A few of these reports used functional magnetic resonance (fMRI) to study activations induced by cortical phosphenes. However, there are no fMRI reports on spontaneous phosphenes originating from the retina and the resulting pattern of cortical activations. We performed fMRI during a reversing checkerboard paradigm in three LCA patients who underwent unilateral gene therapy and reported experiencing frequent phosphene on a daily basis. We observed bilateral cortical activation covering the entire visual cortices when patients reported experiencing phosphenes. In contrast, in the absence of phosphenes, activation was regulated by patient's visual ability and demonstrated improved cortical activation due to gene therapy. These fMRI results illustrate the potential impact of phosphene perception on visual function and they may explain some of the variability that clinicians find in visual function testing in retinal degeneration. Although we did not perform correlations between visual function and phosphenes, we hope data presented here raises awareness of this phenomenon and its potential effect on visual function and the implications for clinical testing. We recommend a thorough history for phosphene experiences be taken in patients with retinal disease who are candidates for gene or molecular therapy. Lastly, these data illustrate the potential power of fMRI as an outcome measure of gene therapy and the negative impact phosphenes may have on vision testing. fMRI has proven to be a sensitive, non-invasive, and reproducible test paradigm for these purposes and can complement standard visual function testing.

Indexed as

Magnetic Resonance ImagingAdultBrainCase-Control StudiesChildComputer SystemsDemographyFemaleHumansLeber Congenital AmaurosisMalePhosphenesPhotic StimulationRetinaVision, OcularYoung Adult

Identifiers

PMID24465873
PMCPMC3897613
OpenAlexW2075922024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.